Acute Exercise and Pancreatic Endocrine Function

Type 2 Diabetes Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01812590
• Other study ID #: Ex-Panc
• Status: Completed
• Phase: N/A
• First received: March 14, 2013
• Last updated: January 30, 2014
• Start date: January 2013
• Est. completion date: October 2013

Study information

• Verified date: January 2014
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Subjects with type 2 diabetes will be stratified into two-quantiles based on ambient hyperglycemia (fasting glucose and HbA1c) and then the effects of a single aerobic exercise bout (1-hour at 50%VO2max) on pancreatic endocrine function will be determined.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: October 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Previous diagnosis with type 2 diabetes, or newly detected in our screening procedures

• Age 30-70 years

• BMI 20-40 kg/m2

Exclusion Criteria:

• Treatment with insulin

• Contraindication to exercise as determined by ECG

• Pregnancy

• Active weight loss in the previous 6 months

• Actively engaged in exercise training programs

• Evidence of chronic pulmonary, cardiovascular, hepatic, renal, or hematological disease

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Behavioral:
• Exercise

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pancreatic endocrine function	Insulin and glucagon secretory responses to intravenous glucose (hyperglycemic clamp 5.4 mmol/l above basal), glucagon-like peptide-1 (0.5 pmol/kg/min), and arginine (5 g injection) will be determined.	24-hours following a period of rest/exercise	No